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Abstract
Background: While the myosin heavy chain IIb isoform (MyHC-IIb) is the predominant motor protein in most
skeletal muscles of rats and mice, the messenger RNA (mRNA) for this isoform is only expressed in a very small
subset of specialized muscles in adult large mammals, including humans.
Results: We identify the DNA sequences limiting MyHC-IIb expression in humans and explore the activation of this
gene in human skeletal muscle. We demonstrate that the transcriptional activity of ~1.0 kb of the human MyHC-IIb
promoter is greatly reduced compared to that of the corresponding mouse sequence in both mouse and human
myotubes in vitro and show that nucleotide differences that eliminate binding sites for myocyte enhancer factor 2
(MEF2) and serum response factor (SRF) account for this difference. Despite these differences, we show that MyHC-
IIb mRNA is expressed in fetal human muscle cells and that MyHC-IIb mRNA is significantly up-regulated in the
skeletal muscle of Duchene muscular dystrophy patients.
Conclusions: These data identify the genetic basis for a key phenotypic difference between the muscles of large
and small mammals, and demonstrate that mRNA expression of the MyHC-IIb gene can be re-activated in human
limb muscle undergoing profound degeneration/regeneration.
Background
At the level of the sarcomere, one of the greatest differ-
ences in gene expression between mouse and human
skeletal muscle is found within the myosin heavy chain
(MyHC) gene family. This gene family consists of one
cardiac specific isoform (MyHC-a), two developmental
isoforms (MyHC-embryonic and MyHC-perinatal), one
specialized eye muscle isoform (MyHC-extraocular), one
isoform that is expressed in both cardiac and skeletal
muscle (MyHC-b) and three skeletal-specific isoforms
(MyHC-IIa, MyHC-IId/x and MyHC-IIb) [1,2]. The
expression of a particular MyHC isoform within an indi-
vidual muscle fibre confers specific morphological, enzy-
matic and functional effects on that muscle fibre such
that MyHC-b-expressing fibres are typically smaller,
slower contracting fibres rich in the enzymes of oxida-
tive metabolism while MyHC-IIb-expressing fibres are
typically larger, faster contracting fibres dependent on
glycolytic pathways of energy generation [3,4].
Of the adult skeletal isoforms, MyHC-b, -IIa and -IIx
are each expressed to varying degrees in both mouse
and human skeletal muscle. However, although MyHC-
IIb is highly expressed at both the messenger RNA
(mRNA) and protein level in murine skeletal muscle,
evidence to date suggests that this isoform is effectively
only expressed at the mRNA level in a very small subset
of specialized muscles in the adult human [5-10]. As
mentioned above, MyHC-IIb expression is typically
associated with high forces of contraction combined
with rapid contractile characteristics and it has been
suggested that the contractile characteristics of MyHC-
IIb may be incompatible with the biomechanical con-
straints of larger muscles [7,11]. Despite this potential
incompatibility, it has also been suggested that the
MyHC-IIb gene might be a target for ‘gene doping’
manipulations designed to improve human athletic per-
formance [12,13]. Given that the human MyHC-IIb
gene is intact, highly conserved with the mouse MyHC-
IIb gene and capable of producing functional, enzymati-
cally active myosin if expressed as recombinant protein
[1,2,9,14], we sought to elucidate the molecular
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MyHC-IIb expression between the mouse and the
human.
Results
The human MyHC-IIb promoter has reduced
transcriptional activity compared to the corresponding
mouse sequence
Given the high identity of the mouse and human MyHC
isoform gene clusters and that ~1.0 kb of the proximal
mouse MyHC-IIb promoter region is sufficient to confer
both muscle and fibre-type specificity [1,15-18], we
began our investigation by aligning ~1.0 kb of the
mouse and human MyHC-IIb promoter regions. This
sequence alignment revealed 79% identity between the
two species across the ~1.0 kb regions (data not shown).
The identity between the mouse and human sequences
for the first 0.2 kb upstream from the TATA box was
94% and an analysis of potential transcription factor
binding sites revealed a similar pattern of muscle-speci-
fic transcription factor binding sites (Figure 1a). Impor-
tantly, both the mouse and human sequences contain a
consensus E-box site, two AT rich regions previously
shown to bind myocyte enhancer factor 2 (MEF2)
[15,16,19,20] and a CArG box motif [16] (Figure 1a).
Based on these results, we performed transient transfec-
tion studies using the mouse and human 1.0 kb upstream
regions in both mouse (C2C12) and human (primary fetal
myotubes) muscle cells. These experiments revealed that
the 1.0 kb human MyHC-IIb promoter was approximately
20% as transcriptionally active as the same length of mouse
IIb sequence in C2C12 cells and ~40% as active in human
myotubes (Figure 1b). Deletion constructs containing only
the proximal 0.2 kb of the promoter region for both species
exhibited diminished activity compared with that of the 1.0
kb constructs but the activity of the human 0.2 kb construct
was still significantly lower than that of the corresponding
mouse construct in both mouse and human cells (Figure
1b). In addition, the activity of a chimeric promoter con-
struct containing the distal human 0.8 kb linked to the
proximal mouse 0.2 kb (Chimera 1) was as high as, or
higher than, that of the 1.0 kb mouse construct (Figure 1b),
while activity of a construct containing the distal mouse 0.8
kb linked to the proximal human 0.2 kb (Chimera 2) was
similar to that of the human 0.2 kb region alone (Figure
1b). These results indicated that much, if not all, of the
reduced activity of the human MyHC-IIb promoter region
could be attributed to the proximal 0.2 kb region.
The reduced transcriptional activity of the human MyHC-
IIb promoter is due to diminished binding of MEF2 and
serum response factor (SRF)
As described above, an in silico analysis of the mouse
and human MyHC-IIb promoter regions revealed
distinct patterns of muscle-specific transcription factor
binding sites. More specifically, the proximal mouse
MyHC-IIb promoter contains two AT rich regions at
-104/-133 (AT1) and -141/-158 (AT2) upstream of the
TATA box previously shown to bind to MEF2 and octa-
mer binding transcription factor 1 (OCT1) (Figure 1a)
[15,16]. Although AT1 is 100% conserved in the human,
the AT2 region has five nucleotides that differ between
the two species, including a base difference (position
-142) in a region known to bind MEF2 (Figure 1a)
[15,16]. Electrophoretic mobility shift assays (EMSA),
using probes for the mouse and human AT2 regions,
indicated that the mouse AT2 region demonstrated
strong binding to a protein present in mouse myotube
nuclear extract that was supershifted by an MEF2-speci-
fic antibody (Figure 2a). This protein binding was not
observed with the human AT2 sequence, although the
human AT2 region did bind a protein from the mouse
myotube nuclear extract that was supershifted by an
OCT1-specific antibody (Figure 2a). The EMSA analysis
of the AT2 region using human myotube nuclear extract
revealed a similar pattern (data not shown), suggesting
that the observed differences in MEF2 binding were not
due to differences in binding affinity between mouse
and human MEF2. These results indicate that the
mouse AT2 region is strongly bound by MEF2 and
OCT1, while the human AT2 region binds OCT1 but
not MEF2.
As mentioned above, the proximal 0.2 kb region of the
mouse promoter also contains a consensus CArG box
motif (CC(A/T)6GG) at position -62 (Figure 1a) [15].
The human sequence, however, contains a single
nucleotide difference that results in a non-consensus
CArG-like motif (CCAAAAAcGG). EMSA, using oligo-
nucleotide probes containing either the mouse or the
human CArG box regions, showed specific binding by
the mouse probe to a protein present in C2C12 myo-
tube nuclear extracts that was supershifted by an SRF-
specific antibody, while the human probe did not bind
this protein (Figure 2a). Both the mouse and human
CArG probes showed similar binding to a second pro-
tein, believed to be nuclear factor 1 (NF1), as this pro-
tein has been previously reported to bind this region of
the mouse MyHC-IIb promoter [15]. The EMSA analy-
sis using human myotube nuclear extract also revealed
binding to the mouse promoter of a protein recognized
by an SRF-specific antibody (data not shown), further
confirming that this CArG box-mediated effect on IIb
expression is a cis-effect and is not due to a deficiency
of SRF protein in human cells. Together, these results
indicate that the CArG motif of the mouse MyHC-IIb
promoter region binds the SRF protein and that a single
base difference within the human sequence greatly
reduces, or abolishes, SRF binding.
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CArG-box regions of the mouse and the human MyHC-
IIb promoters, we used targeted mutagenesis to create
human MyHC-IIb promoter constructs containing either
the mouse AT2 or CArG-box regions. Mutagenesis of
the human AT2 region modestly increased the activity
of this construct (human 1.0 kb mouseAT2) in C2C12
myotubes and had no effect in human myotubes (Figure
Figure 1 Myosin heavy chain IIb (MyHC-IIb) promoter sequence alignment and activity in mouse and human muscle cells. (A) For the
proximal 0.2 kb of the mouse and human MyHC-IIb promoters, the sequence identity was 94%. Both sequences contain a conserved E-Box and
AT rich region (AT1), along with a consensus TATA box. However, the AT2 and CArG box regions contain sequence differences predicted to
affect myocyte enhancer factor 2 (MEF2) and serum response factor (SRF) binding to the human sequence. (B) Activities of the 1.0 kb and 0.2 kb
human constructs were significantly reduced compared to the corresponding mouse sequences in both the mouse and human cells. A chimeric
construct containing the proximal human 0.2 kb region linked to the distal mouse 0.8 kb region (Chimera 2) showed reduced activity compared
to the opposing construct (Chimera 1). Values (mean ± standard error of mean) represent the result of at least three duplicate experiments and
are expressed as fold-activity relative to the mouse 1.0 kb MyHC-IIb reporter plasmid. *P < 0.01 Human 1.0 kb versus Mouse 1.0 kb; **P < 0.05
Human 0.2 kb versus Mouse 0.2 kb; ***P < 0.01 Chimera 2 versus Chimera 1.
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Page 3 of 9Figure 2 Electrophoretic mobility shift assays (EMSA) and transient transfection of site-directed mutagenesis constructs. (A) EMSA
results using radiolabelled probes for the mouse and human AT2 and CArG box regions with C2C12 nuclear extract. The mouse AT2 region
showed strong binding of a protein that was supershifted by a myocyte enhancer factor 2 (MEF2)-specific antibody. The human probe did not
bind this protein, but did bind a protein that was supershifted by an octamer binding transcription factor 1 (OCT1)-specific antibody. The mouse
CArG probe demonstrated strong binding to a protein that was supershifted by a serum response factor (SRF)-specific antibody while the
human probe did not bind this protein. (B) Reporter plasmid transfection results indicated that targeted mutagenesis of the human CArG box
motif (Human 1.0 kb mouseCArG) increased activity of the human MyHC-IIb promoter construct ~fivefold in mouse cells and ~twofold in human
cells, resulting in activity equal to that of the full-length mouse construct. Conversely, replacing the mouse CArG box sequence with the
corresponding human sequence significantly reduced activity of the mutated mouse construct (Mouse 1.0 kb humanCArG) in both mouse and
human cells. Mutagenesis of the human AT2 region (Human 1.0 kb mouseAT2) increased activity ~twofold in mouse cells but had no effect in
human cells. Values (mean ± standard error or mean) represent the result of at least three duplicate experiments and are expressed as fold-
activity relative to the mouse 1.0 kb MyHC-IIb reporter plasmid. *P < 0.05 Human 1.0 kb mouseAT2 or mouseCArG versus Human 1.0 kb; **P <
0.05 Mouse 1.0 kb humanCArG versus Mouse 1.0 kb.
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motif (CCAAAAAcGG) to the mouse sequence
(CCAAAAATGG; human 1.0 kb mouseCArG), increased
activity fivefold in C2C12 myotubes and twofold in
human myotubes, resulting in activity equal to that of
the wild type 1.0 kb mouse construct (Figure 2b). Con-
versely, mutating the mouse CArG to the human
sequence significantly decreased activity of this con-
struct (mouse 1.0 kb humanCArG) and resulted in
activity comparable to that of the wild type 1.0 kb
human construct (Figure 2b). These results suggest that
the CArG box motif in the mouse MyHC-IIb promoter
region is both necessary and sufficient for its relatively
higher-level activity.
The human MyHC-IIb promoter region is responsive to
stimuli and MyHC-IIb messenger RNA (mRNA) is
expressed in fetal human muscle cells and Duchene
muscular dystrophy biopsy samples
As the human MyHC-IIb gene has remained under evo-
lutionary constraint and the promoter is not functionally
inactive (albeit transcriptionally repressed relative to the
mouse), we asked whether the human MyHC-IIb pro-
moter was capable of responding to other transcription
factors known to influence MyHC gene activity. In
order to test this, we analysed the affects of over-expres-
sion of MyoD, myogenin or calcineurin on the activity
of the mouse and human 1.0 kb constructs. In each
case, the relative fold-activation in response to these fac-
tors was similar for both the mouse and human promo-
ter constructs, although the absolute levels of activity
remained lower for the human construct compared to
the mouse construct (Figure 3a and data not shown). Of
the three transcription factors analysed, MyoD over-
expression had the greatest effect on MyHC-IIb promo-
ter construct activity (Figure 3a).
Having demonstrated that the human IIb promoter is
capable of responding to factors known to influence
MyHC gene expression, we then wished to see if we
could find evidence of MyHC-IIb mRNA expression in
human muscle cells. In fact, MyHC-IIb mRNA was sig-
nificantly increased with differentiation in primary fetal
human myotubes (Figure 3b) and, after 5 days of differ-
entiation, the level of MyHC-IIb mRNA expression was
comparable to that of the other adult skeletal MyHC
isoforms (MyHC-b,- I I aa n d- I I d / x ;F i g u r e3 c ) .G i v e n
that muscle fibre regeneration is characterized by a re-
capitulation of developmental programmes of gene
expression that includes re-expression of the develop-
mental myosin heavy chain isoforms and myogenic reg-
ulatory factors [19-22], we also wished to see if there
was any evidence of MyHC-IIb expression in post-natal
human muscle undergoing regeneration in response to
muscular disease. Intriguingly, we observed a significant
increase in MyHC-IIb mRNA in Duchene muscular dys-
trophy (DMD) leg muscle biopsy samples compared
with leg muscle biopsy samples from healthy control
subjects or patients with muscular dystrophies not char-
acterized by rounds of degeneration and regeneration
[limb-girdle muscular dystrophy (LGMD) or spinal mus-
cular atrophy (SMA); Figure 3d]. Overall, these results
indicate that, although the basal transcriptional activity
of the human MyHC-IIb promoter is reduced relative to
that of the mouse promoter, the human promoter is
responsive to myogenic factors and MyHC-IIb mRNA is
expressed in vitro in developing fetal myotubes and in
vivo with severe muscle fibre degeneration/regeneration.
Discussion
MyHC is the molecular motor for muscle contraction
and distinct expression patterns of expression for the
individual MyHC isoforms, each with its own unique
functional properties, allows for a broad range of muscle
fibre contractile characteristics along with the elegant
adaptability of skeletal muscle to alterations in activation
state. In addition to spatial and temporal variations in
MyHC gene expression, there are also species-depen-
dent variations in MyHC gene expression. This species-
to-species variation in MyHC isoform expression is, per-
haps, most notable for MyHC-IIb, which is the predomi-
nant MyHC isoform expressed in most small rodent
muscles yet effectively not expressed in the vast majority
of adult human skeletal muscle [6,7,10]. Although it has
been hypothesized that the contractile characteristics of
MyHC-IIb are somehow incompatible with human (and
other large mammal) muscle architecture, the underly-
ing molecular reason(s) why the gene is not expressed
in the vast majority of human skeletal muscle remains
unknown. Given that the human MyHC-IIb gene is
intact and highly conserved with the corresponding
mouse gene, our intent was to elucidate the molecular
mechanism for this marked species difference in gene
expression.
Our findings show that, despite highly conserved
upstream regulatory regions, the mouse and human
MyHC-IIb genes exhibit dramatically different basal
transcriptional activities in both mouse and human
muscle cells (Figure 1). In silico analysis combined with
deletional and site-directed mutagenic analyses revealed
that the low transcriptional activity of the human
MyHC-IIb gene is largely the result of reduced MEF2
and SRF binding within the proximal promoter region
(Figure 2). Remarkably, much of the difference in tran-
scriptional activity between the mouse and human
MyHC-IIb genes can be attributed to a single nucleotide
difference between the two species that effectively elimi-
nates SRF binding to the proximal human MyHC-IIb
promoter region (Figure 2), although we can not rule
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of the ~1.0 kb used in these studies that may also contri-
bute to the low in vivo expression of the human gene.
In both mouse and human cells, the human MyHC-
IIb promoter region was responsive to MyoD, myogenin
and calcineurin over-expression. These data indicate
that, while SRF binding to the CArG motif (and, to a
lesser extent, MEF2 binding to the AT2 region) is criti-
cal for establishing basal expression, transcriptional
activity of the human MyHC-IIb promoter can be
induced by other key myogenic regulatory factors. With
respect to calcineurin, it is likely that this regulation is
modulated via one or both of the consensus nuclear fac-
tor of activated T cells (NFAT) binding motifs found in
the proximal ~1.0 kb human MyHC-IIb promoter
region (-608/-617 and -682/-690).
However, despite reduced basal activity our findings
indicate that MyHC-IIb mRNA is expressed in primary
fetal human muscle cells in vitro (Figure 3). These data
led us to hypothesize that the human MyHC-IIb promo-
ter region may be active in developing human muscula-
ture and in human tissue undergoing muscle fibre
regeneration, as this process is characterized by fetal
patterns of gene expression including the expression of
developmental MyHC isoforms and potent myogenic
regulatory factors such as MyoD. In fact, investigation
of MyHC expression in human muscular disorders char-
acterized by severe muscle fibre degeneration/regenera-
tion demonstrated a significant up-regulation of MyHC-
IIb mRNA in DMD patients but not in patients with
muscle disorders characterized by less severe muscle
degeneration/regeneration (LGMD or SMA; Figure 3).
Figure 3 Myosin heavy chain IIb isoform (MyHC-IIb) promoter responsiveness and messenger RNA (mRNA) expression in human
muscle cells. (A) The mouse and human 1.0 kb MyHC-IIb promoter regions were equally responsive to myogenic regulatory factor (MyoD,
myogenin and calcineurin (CN)) over-expression in both mouse and human cells. (B) MyHC-IIb mRNA expression was significantly greater in
primary fetal human myotubes (MT) compared to confluent myoblasts (MB). (C) In differentiated (day 5) human myotubes, the level of MyHC-IIb
mRNA expression was comparable to that seen for MyHC-b, -IIa and IId/x. Overall, MyHC-Embryonic demonstrated the highest relative expression
and MyHC-Perinatal the lowest. (D) MyHC-IIb mRNA expression was significantly increased in Duchene muscular dystrophy (DMD) biopsy
samples (n = 7) compared to healthy control samples (n = 7), limb-girdle muscular dystrophy (LGMD) samples (n = 4) or spinal muscular atrophy
(SMA) samples (n = 2). Values represent mean ± standard error of mean and are the result of at least three duplicate experiments. *P < 0.05
versus control or green fluorescent protein (GFP); **P < 0.01 versus confluent myoblasts or control, ***P < 0.05 versus MyHC-IIb.
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responds robustly to MyoD over-expression and that
MyoD is strongly induced in DMD [19], this observed
increase in MyHC-IIb mRNA expression in the DMD
samples is likely attributed to MyoD-mediated trans-
activation of the human gene.
Although this evidence of increased MyHC-IIb mRNA
expression in fetal human myotubes and in DMD skeletal
muscle is intriguing, we have not been able to find com-
pelling evidence of MyHC-IIb protein expression in these
same samples. Immunohistochemical analyses using the
MyHC-IIb-specific antibody BF-F3 [23] appeared to indi-
cate an increased immunoreactivity in DMD samples as
compared to control samples but the data were inconsis-
tent. Similarly, while mass spectroscopy detected a small
number of peptides attributed to MyHC-IIb in both con-
trol and DMD protein isolates, the data did not provide a
quantitative assessment of the relative degree of MyHC-
IIb protein expression in the two conditions. Our inabil-
ity to find evidence of MyHC-IIb protein, despite signifi-
cant activation of the mRNA transcript, parallels the
results of Horton et al. ,w h oa l s od e m o n s t r a t e dM y H C -
IIb mRNA expression in the apparent absence of MyHC-
IIb protein in the human masseter [9]. Our data, com-
bined with these previous data, indicate that MyHC-IIb
expression in the human may be subject to both tran-
scriptional and post-transcriptional control.
Conclusions
Overall, our data provide the first in-depth analysis of the
factors controlling transcriptional activation of the human
MyHC-IIb gene and identify key genomic sequence differ-
ences that apparently account for the reduced transcrip-
tional activity of the human MyHC-IIb gene relative to
that of the mouse gene. We also provide the first evidence
that MyHC-IIb mRNA is expressed in fetal human myo-
tubes and is up-regulated in diseased human skeletal mus-
cle undergoing severe muscle fibre degeneration/
regeneration. Although these data are intriguing, any spec-
ulation on the possible functional significance of MyHC-
IIb expression during human development or in the
regeneration of human skeletal muscle is limited without
any compelling evidence of MyHC-IIb protein expression
across these conditions. Further studies across the devel-
opmental time points and muscle groups, along with a
more extensive analysis of skeletal muscle disease states,
may help to determine if, in fact, MyHC-IIb protein is
expressed in the human and if the expression of this myo-
sin has any functional consequences.
Methods
Cloning and cell culture
The human MyHC-IIb promoter region was identified
by a pairwise BLAST search using the previously
identified mouse 1.0 kb MyHC-IIb promoter region and
human chromosome 17, clone hRPK.799_N_11
sequence (AC005323). Mouse and human MyHC-IIb
promoter regions were then amplified by polymerase
chain reaction (PCR) and cloned into a Firefly luciferase
reporter plasmid (VR1255, Vical, CA, USA) at MSCI
a n dS A C I I .D e l e t i o na n dc h i m e r i cc o n s t r u c t sw e r ec r e -
ated using PCR and inverse-PCR with the 1.0 kb mouse
and human plasmids as template DNA. Site-directed
mutagenesis was performed using inverse-PCR. C2C12
mouse myoblasts were grown in Dulbecco’s modified
eagle medium (DMEM)(Invitrogen, CA, USA) with 20%
fetal bovine serum (FBS). Primary fetal human myo-
blasts were grown in DMEM with 15% fetal bovine
serum (FBS) and 0.05% chick embryo extract (Invitro-
gen). Both mouse and human myoblasts were differen-
tiated in DMEM containing 1% horse serum (HS).
MyHC-IIb promoter plasmids were transfected into
C2C12 mouse myoblasts at 85% to 95% confluency
using Lipofectamine 2000 (Invitrogen) according to
manufacturer’s instructions. Human myoblasts were
transfected at 85% to 95% confluency using GeneJuice
(Novagen, WI, USA) according to manufacturer’s
instructions. All transfections included a thymidine
kinase-Renilla luciferase construct (Promega, WI, USA)
at a 4:1 ratio (IIb promoter construct: pRLTK) as an
internal control. For MyoD over-expression analysis,
mouse and human ~1.0 kb IIb promoter plasmids were
co-transfected with either a control vector (cytomegalo-
virus-b-galactosidase) or a MyoD expression vector at a
1:1 ratio (IIb plasmid: control vector or MyoD vector).
For myogenin and calcineurin over-expression analysis,
cells were transfected at 70% to 80% confluency, as
described above, and then infected the following day
with either a green fluorescent protein (control), myo-
genin, or calcineurin-expressing adenoviral vector at a
multiplicity of infection (MOI) of 50. Following transfec-
tions, confluent cells were differentiated in DMEM with
1% HS for 3 to 5 days at which time, cells were lysed in
1x Passive Lysis Buffer (Prom e g a )a n da s s a y e df o rr e l a -
tive luciferase levels (Firefly/Renilla) using a dual lucifer-
ase reporter assay system (Promega) according to
manufacturer’s instructions.
Electrophoretic mobility shift assays
Double-stranded,
32P radiolabelled probes (100,000 to
150,000 cpm) containing the mouse/human AT2 regions
(Mouse AT2 sense 5’-TAGATCATCCCCTGTCAAATT
ATTTATAGATGA-3’,a n t i s e n s e5 ’-TTGTCATCTA-
TAAATAATTTGACAGGGGATGAT-3’;H u m a nA T 2
sense 5’-TAGATCATCCTCTGTTAAATTATTTAT
GGGTGT-3’,a n t i s e n s e5 ’-TTGACACCCATAAA-
TAATTTAACAGAGGATGAT-3’)a n dt h em o u s e /
human CArG box regions (Mouse CArG sense 5’-
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CAAGTA-3’,a n t i s e n s e5 ’-ACCTACTTGGCAAAAC-
CATTTTTGGCAATCTCTTTA-3’,a n dH u m a nC A r G
sense 5’-GTGCAAAGAGATTGCCAAAAACGGTTTTG
CCAAGTA-3’,a n t i s e n s e5 ’-ACCTACTTGGCAAAA
CCGTTTTTGGCAATCTCTTTG-3’) were incubated
with 8-12 μg of nuclear extract isolated from either
C2C12 mouse myotubes or primary human myotubes in
t h ep r e s e n c eo ra b s e n c eo fa n t i b o d i e ss p e c i f i ct oM E F 2 ,
OCT1, or SRF (Santa Cruz Biotechnology, Inc, CA,
USA). Following incubation, samples were run on a 4%
acrylamide binding gel at 300 V for 1 hour and visua-
lized with a Storm PhosphorImager (Molecular
Dynamics, CA, USA).
Human MyHC-IIb mRNA expression analysis
DMD, LGMD and SMA biopsy samples were kindly
provided by Dr E Hoffman. Control muscle biopsy sam-
ples were surgically isolated from the vastus medialis in
sedentary college-age men and were collected in
Boulder, Colorado, USA. All protocols were approved
by the Human Research Committee, University of Col-
orado at Boulder, Boulder, Colorado, USA. Total RNA
was isolated from human myotubes or biopsy samples
using TRI Reagent (Molecular Research Center, Inc,
Ohio, USA) according to manufacturer’s instructions
and stored at -80°C. Following DNase treatment (Turbo
DNase, Applied Biosystems/Ambion, TX, USA), first-
strand cDNA was synthesized using reverse transcriptase
(SuperScript II, Invitrogen), random hexamers (Invitro-
gen) and 2 μg of total RNA according to manufacturer’s
instructions. Quantitative real-time PCR was performed
using the absolute quantification (standard curve)
method with gene specific primers and SYBR Green
(Applied Biosystems 7500 System, CA, USA). The fol-
lowing MyHC isoform-specific primers were used:
MyHC-Embryonic sense 5’-CCTTCTGGAGCAGGACA-
GAA-3’,a n t i s e n s e5 ’-CAAAGCAAAGTTTATTG-
CATGTG-3’; MyHC-Perinatal sense 5’-TAAAC
ACACCTGCCTGATGC-3’,a n t i s e n s e5 ’-TCAGCTT-
TAACAGGAAAATAAACG-3’;M y H C - b sense 5’-
TGCCACATCTTGATCTGCTC-3’;a n t i s e n s e5 ’-
CTCGGCTTCAAGGAAAATTG-3’; MyHC-IIa sense 5’-
CTGATGCCATGGAATGACTG-3’,a n t i s e n s e5 ’-
CCCTATGCTTTATTTCCTTTGC-3’; MyHC-IId/x
sense 5’-ACATTGCTGAGTCCCAGGTC-3’,a n t i s e n s e
5’-TCTTTGGTCACCTTTCAGCA-3’; MyHC-IIb sense
5’-CAAGAGACAAGCTGAAGAGGCT -3’, antisense 5’-
GATATACAGGACAGTGACAAAGAACT -3’.D u et o
the high identity across MyHC isoforms, the MyHC-IIb
PCR product was sequenced and confirmed to be
MyHC-IIb. Alpha-skeletal actin (sense 5’-CGACAT-
CAGGAAGGACCTGTATGCC-3’;a n t i s e n s e5 ’-
GGCCTCGTCGTACTCCTGCTTGG-3’) or ribosomal
18 S (sense 5’-GCCGCTAGAGGTGAAATTCTT-3’;
antisense 5’-CTTTCGCTCTGGTCCGTCTT-3’)w a s
used as the normalizing gene (18 S for fetal myoblast
cell culture experiments; a-skeletal actin for biopsy
experiments).
Statistical analysis
All data are presented as mean ± standard error of
mean. Data were analysed for statistical significance
using Statview™ 5.0 statistical software (SAS Institute,
NC, USA). Results were analysed with ANOVA com-
bined with the Fishers paired least significant difference
post hoc test, with statistical significance set at P < 0.05.
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